References
1. Collett MS, Erikson RL (1978) Protein kinase activity associated with the avian sarcoma virus
SRC gene product. Proc Natl Acad Sci 75(4):2021–2024
2. Castagna M et al (1982) Direct activation of calcium-activated, phospholipid-dependent
protein kinase by tumor-promoting phorbol esters. J Biol Chem 257(13):7847–7851
3. Hidaka H et al (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic
nucleotide-dependent protein kinase and protein kinase C. Biochemistry 23(21):5036–5041
4. Knighton D et al (1991) Crystal structure of the catalytic subunit of cyclic adenosine
monophosphate-dependent protein kinase. Science 253(5018):407–414
5. Zheng J et al (1993) Crystal structures of the myristylated catalytic subunit of cAMPdependent protein kinase reveal open and closed conformations. Protein Sci 2(10):1559–1573
6. Yaish P et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase
inhibitors. Science 242(4880):933–935
7. Kovalenko M et al (1994) Selective platelet-derived growth factor receptor kinase blockers
reverse sis-transformation. Cancer Res 54(23):6106–6114
8. Gazit A et al (1996) Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor
tyrosine kinase: structureÀactivity relationships in quinoxalines, quinolines, and indole
tyrphostins. J Med Chem 39(11):2170–2177
9. Osherov N et al (1993) Selective inhibition of the epidermal growth factor and HER2/neu
receptors by tyrphostins. J Biol Chem 268(15):11134–11142
10. Levitzki A, Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu Rev
Biochem 75(1):93–109
11. Hunter T (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib.
J Clin Invest 117(8):2036–2043
12. Roskoski R Jr (2020) FDA-approved protein kinase inhibitors. Blue Ridge Institute for
Medical Research, Horse Shoe
13. Bhullar KS et al (2018) Kinase-targeted cancer therapies: progress, challenges and future
directions. Mol Cancer 17(1):48
14. Manning G et al (2002) The protein kinase complement of the human genome. Science 298
(5600):1912–1934
15. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol
Phys 59(2, Supplement):S21–S26
16. Oda K et al (2005) A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol 1:2005.0010
17. Lee HJ et al (2015) Prognostic and predictive values of EGFR overexpression and EGFR copy
number alteration in HER2-positive breast cancer. Br J Cancer 112(1):103–111
18. Yang C-H et al (2015) EGFR over-expression in non-small cell lung cancers harboring EGFR
mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta 1852
(7):1540–1549
19. Bossi P et al (2016) Prognostic and predictive value of EGFR in head and neck squamous cell
carcinoma. Oncotarget 7(45):74362–74379
20. Gan HK, Cvrljevic AN, Johns TG (2013) The epidermal growth factor receptor variant III
(EGFRvIII): where wild things are altered. FEBS J 280(21):5350–5370
21. An Z et al (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling
pathways and targeted therapies. Oncogene 37(12):1561–1575
22. Han J et al (2015) CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII
enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5:11483
23. Sacher AG et al (2016) Prospective validation of rapid plasma genotyping for the detection of
EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2(8):1014–1022
24. De Silva N et al (2015) Molecular effects of Lapatinib in the treatment of HER2
overexpressing oesophago-gastric adenocarcinoma. Br J Cancer 113:1305
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
145
1. Collett MS, Erikson RL (1978) Protein kinase activity associated with the avian sarcoma virus
SRC gene product. Proc Natl Acad Sci 75(4):2021–2024
2. Castagna M et al (1982) Direct activation of calcium-activated, phospholipid-dependent
protein kinase by tumor-promoting phorbol esters. J Biol Chem 257(13):7847–7851
3. Hidaka H et al (1984) Isoquinolinesulfonamides, novel and potent inhibitors of cyclic
nucleotide-dependent protein kinase and protein kinase C. Biochemistry 23(21):5036–5041
4. Knighton D et al (1991) Crystal structure of the catalytic subunit of cyclic adenosine
monophosphate-dependent protein kinase. Science 253(5018):407–414
5. Zheng J et al (1993) Crystal structures of the myristylated catalytic subunit of cAMPdependent protein kinase reveal open and closed conformations. Protein Sci 2(10):1559–1573
6. Yaish P et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase
inhibitors. Science 242(4880):933–935
7. Kovalenko M et al (1994) Selective platelet-derived growth factor receptor kinase blockers
reverse sis-transformation. Cancer Res 54(23):6106–6114
8. Gazit A et al (1996) Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor
tyrosine kinase: structureÀactivity relationships in quinoxalines, quinolines, and indole
tyrphostins. J Med Chem 39(11):2170–2177
9. Osherov N et al (1993) Selective inhibition of the epidermal growth factor and HER2/neu
receptors by tyrphostins. J Biol Chem 268(15):11134–11142
10. Levitzki A, Mishani E (2006) Tyrphostins and other tyrosine kinase inhibitors. Annu Rev
Biochem 75(1):93–109
11. Hunter T (2007) Treatment for chronic myelogenous leukemia: the long road to imatinib.
J Clin Invest 117(8):2036–2043
12. Roskoski R Jr (2020) FDA-approved protein kinase inhibitors. Blue Ridge Institute for
Medical Research, Horse Shoe
13. Bhullar KS et al (2018) Kinase-targeted cancer therapies: progress, challenges and future
directions. Mol Cancer 17(1):48
14. Manning G et al (2002) The protein kinase complement of the human genome. Science 298
(5600):1912–1934
15. Herbst RS (2004) Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol
Phys 59(2, Supplement):S21–S26
16. Oda K et al (2005) A comprehensive pathway map of epidermal growth factor receptor
signaling. Mol Syst Biol 1:2005.0010
17. Lee HJ et al (2015) Prognostic and predictive values of EGFR overexpression and EGFR copy
number alteration in HER2-positive breast cancer. Br J Cancer 112(1):103–111
18. Yang C-H et al (2015) EGFR over-expression in non-small cell lung cancers harboring EGFR
mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta 1852
(7):1540–1549
19. Bossi P et al (2016) Prognostic and predictive value of EGFR in head and neck squamous cell
carcinoma. Oncotarget 7(45):74362–74379
20. Gan HK, Cvrljevic AN, Johns TG (2013) The epidermal growth factor receptor variant III
(EGFRvIII): where wild things are altered. FEBS J 280(21):5350–5370
21. An Z et al (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling
pathways and targeted therapies. Oncogene 37(12):1561–1575
22. Han J et al (2015) CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII
enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5:11483
23. Sacher AG et al (2016) Prospective validation of rapid plasma genotyping for the detection of
EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2(8):1014–1022
24. De Silva N et al (2015) Molecular effects of Lapatinib in the treatment of HER2
overexpressing oesophago-gastric adenocarcinoma. Br J Cancer 113:1305
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
145